{
  "asset": "pasritamig",
  "query_terms": [
    "pasritamig"
  ],
  "returned_unique": 5,
  "kept": 5,
  "studies": [
    {
      "nct_id": "NCT07319871",
      "title": "A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Pasritamig",
        "JNJ-86974680"
      ],
      "last_update": "2026-01-06",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07319871"
    },
    {
      "nct_id": "NCT07225946",
      "title": "A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Pasritamig",
        "Docetaxel",
        "Prednisone"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07225946"
    },
    {
      "nct_id": "NCT07164443",
      "title": "A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Metastatic Castration-resistant Prostate Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Pasritamig",
        "Placebo",
        "Best Supportive Care (BSC)"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07164443"
    },
    {
      "nct_id": "NCT06095089",
      "title": "A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Advanced Prostate Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "JNJ-78278343",
        "JNJ-87189401"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06095089"
    },
    {
      "nct_id": "NCT07082920",
      "title": "A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "JNJ-78278343",
        "JNJ-95298177"
      ],
      "last_update": "2025-12-17",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07082920"
    }
  ]
}